Chimeric antigen receptor T-cell therapy for refractory post-transplant lymphoproliferative disorder after lung transplantation

Chimeric antigen receptor T-cell therapy (CAR-T) has been used to treat refractory post-transplant lymphoproliferative disorder (PTLD) in solid organ transplant patients, including heart, kidney, liver, intestine, and pancreas. We report the use of CAR-T for treating refractory PTLD in a 73-year-old...

Full description

Saved in:
Bibliographic Details
Published in:JHLT Open 2024-08, Vol.5, p.100101, Article 100101
Main Authors: Veit, Kaleb, Peña, Tahuanty, Klesney-Tait, Julia, Mou, Eric, Farooq, Umar
Format: Article
Language:English
Subjects:
CAR-T
chimeric antigen receptor T-cell therapy
lung transplant
lymphoma
post-transplant lymphoproliferative disorder
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chimeric antigen receptor T-cell therapy (CAR-T) has been used to treat refractory post-transplant lymphoproliferative disorder (PTLD) in solid organ transplant patients, including heart, kidney, liver, intestine, and pancreas. We report the use of CAR-T for treating refractory PTLD in a 73-year-old female who was 7 years post bilateral lung transplantation for idiopathic pulmonary fibrosis. We discuss the immunosuppression management in this patient, as well as her clinical course and outcome.
ISSN:2950-1334
2950-1334
DOI:10.1016/j.jhlto.2024.100101